Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

If your weight loss goals have taken a backward step, this simple device might be all you need to get back on track and shed ...

Buy two months of either the Semaglutide or Tirzepatide, and get the third month free, for a limited time only.

Analysts have deemed LLY stock a “Strong Buy,” with an average target price of $984.29, indicating an upside potential of 12.1% from Friday’s closing price. Among the 24 analysts covering the stock, ...

For its most recently reported quarter (Q3 of 2024), Hims & Hers generated $401.6 million in revenue. That resulted in a free ...